Despite strong international evidence supporting low-dose aspirin for the prevention of preeclampsia, its use remains inconsistent in many developing countries, and evidence from local populations is limited. Further evaluation of its effectiveness among high-risk primigravida women may help inform appropriate clinical use and contribute to reducing adverse maternal and neonatal outcomes associated with preeclampsia.
